Dogwood Therapeutics Q2 FY26 net loss widens to $11.5 million - DWTX News | RalliesDogwood Therapeutics Q2 FY26 net loss widens to $11.5 million
D
DWTX• Q2 results and expense drivers
- Dogwood Therapeutics posted a Q2 net loss attributable to common stockholders of $11.5 million, or $0.34 a share.
- R&D expense rose to $3.25 million from $2.57 million a year earlier, due to higher Halneuron Phase 2b CINP study costs.
- G&A expense increased to $1.63 million from $1.35 million, on higher salaries and related personnel costs.
- The company booked a $6.7 million net non-cash impairment charge tied to goodwill and IPR&D, including a $9.2 million IPR&D impairment.
- Cash totaled $9.61 million; the Halneuron Phase 2b CINP trial had 217 patients enrolled, with top-line results expected in fall 2026.
TSLA
•
